The Lancet study unveils exciting findings on retatrutide as a novel treatment for type 2 diabetes

FHS
June 29, 2023
9:41 am

Researchers performed a phase II randomized clinical trial (RCT).

Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms

Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19.

November 22, 2023

New acoustic tweezers isolate viruses from saliva with high precision

Developing antiviral therapeutics and vaccines requires close study of the viruses that cause disease. But how can these small germs be isolated from complex biological

September 11, 2024

Unlocking the secrets of our body’s first line of defense against strep throat and more

Researchers have mapped the complex structures of secretory immunoglobulin A (sIgA) in interaction with human CD89 and Streptococcus pyogenes M4, offering new insights into how

September 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.